Primary myocardial involvement in systemic sclerosis: Evidence for a microvascular origin

Clinical and Experimental Rheumatology

Volumn 28, Issue 5 SUPPL. 62, 2010, Pages

  Allanore, Y ^a   Meune, C ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE   (France)

Author keywords

Calcium channel blockers; Myocardium; Systemic sclerosis; Vasospasm

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; NICARDIPINE; NIFEDIPINE; PROSTANOID; VASODILATOR AGENT;

ATHEROSCLEROSIS; BLOOD VESSEL REACTIVITY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART VENTRICLE FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MICROCIRCULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN FIBROSIS; STROKE; SYSTEMIC SCLEROSIS; SYSTOLIC DYSFUNCTION; TISSUE DOPPLER IMAGING; VASCULAR LESION;

CORONARY CIRCULATION; CORONARY VESSELS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FIBROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MICROVESSELS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; SCLERODERMA, SYSTEMIC;

EID: 78650529151     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. MEUNE C, VIGNAUX O, KAHAN A, ALLANORE Y: Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010;103:46-52.
2. ALLANORE Y, MEUNE C, KAHAN A: Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol 2008;20:697-702.
3. CANDELL-RIA J. ARMADANS-GIL L, SIMEÓN CP et al.: Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:1138-45.
4. FERRI C, EMDIN M, NIELSEN H, BRUHLMANN P: Assessment of heart involvement. Clin Exp Rheumatol 2003;21(Suppl. 29):S24-8.
5. CLEMENTS PJ, LACHENBRUCH PA, FURST DE, PAULUS HE, STERZ MG: Cardiac score. A semiquantitative measure of cardiac involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1991;34:1371-80.
6. FURST DE, CLEMENTS PJ, HILL S et al.: Immunosuppression with chlorambucil versus placebo in scleroderma; results of a three-year parallel, randomized double blind study. Arthritis Rheum 1989;32:584-593.
7. STEEN VD, MEDSGER TA Jr: Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
8. FERRI C, VALENTINI G, COZZI F et al.: Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc). Systemic sclerosis: demographic, clinical, and serologic features and survival in 1, 012 Italian patients. Medicine (Baltimore) 2002;81:139-53.
9. SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002;81:154-67.
10. IOANNIDIS JP, VLACHOYIANNOPOULOS PG, HAIDICH AB et al.: Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
11. ALLANORE Y, AVOUA CJ, KAHA NA: Systemic sclerosis: an update in 2008. Joint Bone Spine 2008;75:650-5.
12. BULKLEY BH, RIDOLFI RL, SALYER WR, HUTCHINS GM: Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976;53:483-490.
13. JAMES TN: De Subitaneis morbitus. VIII. Coronary arteries and conduction system in scleroderma heart disease. Circulation 1974;50:844-856.
14. FOLLANSBEE W, CURTISS E, MEDSGER TA, OWENS GR, STEEN VD, RODNAN GP: Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. Am J Med 1984;77:489.
15. FOLLANSBEE W, CURTISS E, MEDSGER TA et al.: Physiologic abnormalities of cardiac function in progressive systemic sclerosïs with diffuse scleroderma. N Engl J Med 1984;310:142-8.
16. KAHAN A, NITENBERG A, FOULT JM et al.: Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985;28:637-46.
17. MONTISCI R, VACCA A, GARAU P et al.: Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis 2003;62:890-3.
18. SULLI A, GHIO M, BEZANTE GP et al.: Blunted coronary flow reserve in systemic sclerosis. Rheumatology (Oxford) 2004;43:505-9.
19. PANTING JR, GATEHOUSE PD, YANG GZ et al.: Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med 2002;346:1948-53.
20. MEUNE C, TOUZÉ E, TRINQUART L, ALLANORE Y: Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13.
21. MEUNE C, TOUZE E, TRINQUART L, ALLANORE Y: High risk of clinical cardiovascular events in Rheumatoid arthritis: levels of associations of MI and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;10:3253-6
22. SHERER Y, ZINGER H, SHOENFELD Y: Atherosclerosis in systemic lupus erythematosus. Autoimmunity 2010;43:98-102.
23. D'ANGELO WA, FRIES JF, MASI AT, SHULMAN LE: Pathologic observations in systemic sclerosis (scleroderma). A study of fiftyeight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
24. DERK CT, JIMENEZ SA: Acute myocardial infarction in systemic sclerosis patients: a case series. Clin Rheumatol 2007;26:965-8.
25. KHURMA V, MEYER C, PARK GS et al.: A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum 2008;59:591-7.
26. MOK MY, CHIU SS, LO Y et al.: Coronary atherosclerosis using computed tomography coronary angiography in patients with systemic sclerosis. Scand J Rheumatol 2009;38:381-5.
27. AKRAM MR, HANDLER CE, WILLIAMS M et al.: Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 2006;45:1395-8.
28. COLACI M, SEBASTIANI M, GIUGGIOLI D et al.: Cardiovascular risk and prostanoids in systemic sclerosis. Clin Exp Rheumatol 2008;26:333-6.
29. HETTEMA ME, BOOTSMA H, KALLENBERG CG: Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford) 2008;47:578-83.
30. GUSTAFSSON R, MANNTING F, KAZZAM E, WALDENSTROM A, HALLGREN R: Coldinduced reversible myocardial ischaemia in systemic sclerosis. Lancet 1989;2:475-9.
31. ALEXANDER EL, FIRESTEIN GS, WEISS JL et al.: Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis. Ann Intern Med 1986;105:661-8.
32. LONG A, DUFFY G, BRESNIHAN B: Reversible myocardial perfusion defects during cold challenge in scleroderma. Br J Rheumatol 1986;25:158-61.
33. STEEN VD, FOLLANSBEE WP, CONTE CG, MEDSGER TA Jr: Thallium perfusion defects predict subsequent cardiac dysfunction in patients with systemic sclerosis. Arthritis Rheum 1996;39:677-81.
34. MIZUMO R, FUJIMOTO S, SAITO Y, NAKAMURA S: Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study. Eur J Heart Fail 2010;12:268-75.
35. KAHAN A, DEVAUX JY, AMOR B et al.: Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986;314:1397-402.
36. KAHAN A, DEVAUX JY, AMOR B et al.: Pharmacodynamic effect of dipyridamole on thallium-201 myocardial perfusion in progressive systemic sclerosis with diffuse scleroderma. Ann Rheum Dis 1986;45:718-25.
37. KAHAN A, DEVAUX J Y, AMOR B: Nicardipine improves myocardial perfusion in systemic sclerosis. J Rheumatol 1988, 15:1395-400.
38. KAHAN A, DEVAUX JY, AMOR B: The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin Pharmacol Ther 1990;47:483-9.
39. ISHIDA R, MURATA Y, SAWADA Y: Thallium-201 myocardial SPET in patients with collagen disease. Nucl Med Commun 2000;21:729-34.
40. NAGEL E, KLEIN C, PAETSCH I et al.: Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation 2003;108:432-7.
41. VIGNAUX O, ALLANORE Y, MEUNE C et al.: Evaluation of nifedipine efficacy on myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis. 2005;64:1268-73.
42. ALLANORE Y, MEUNE C, VIGNAUX O, WEBER S, LEGMANN P, KAHAN A: Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. J Rheumatol 2006;33:2464-9.
43. TZELEPIS GE, KELEKIS NL, PLASTIRAS SC et al.: Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum. 2007;56:3827-36.
44. HACHULLA AL, LAUNAY D, GAXOTTE V et al.: Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients. Ann Rheum Dis 2009;68:1878-84.
45. KOBAYASHI H, YOKOE I, HIRANO M et al.: Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis. J Rheumatol 2009;36:106-12.
46. FOLLANSBEE WP, MILLER TR, CURTISS EI: A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990;17:656-62.
47. KAZZAM E, WALDENSTROM A, LANDELIUS J, HALLGREN R, ARVIDSSON A, CAIDAHL K: Non-invasive assessment of left ventricular diastolic function in patients with systemic sclerosis. J Intern Med 1990;228:183-92.
48. KAHAN A, DEVAUX JY, AMOR B et al.: Pharmacodynamic effect of nicardipine on left ventricular function in systemic sclerosis. J Cardiovasc Pharmacol 1990;15:249-53.
49. ARMSTRONG GP, WHALLEY GA, DOUGHTY RN: Left ventricular function in scleroderma. Br J Rheumatol 1996;35:983-8.
50. HEGEDUS I, CZIRJAK L: Left ventricular wall motion abnormalities in 80 patients with systemic sclerosis. Clin Rheumatol 1995;14:161-4.
51. MEUNE C, ALLANORE Y, DEVAUX JY et al.: High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. J Rheumatol 2004;31:1941-5.
52. VALENTINI G, VITALE DF, GIUNTA A: Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve. Ann Rheum Dis 1996;55:455-60.
53. MEUNE C, ALLANORE Y, PASCAL O et al.: Reliable detection of early myocardial dysfunction by tissue Doppler echocardiography as compared with conventional techniques in patients with systemic sclerosis. Eur J Echocardiography 2005;6:351-7.
54. MAIONE S, CUOMO G, GIUNTA A et al.: Echocardiography alterations in systemic sclerosis: A longitudinal study. Semin Arthritis Rheum 2005;34:721-7.
55. MEUNE C, AVOUAC J, WAHBI K et al.: Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography in routine care: a controlled study of 100 consecutive patients. Arthritis Rheum 2008;58:1803-9.
56. ALLANORE Y, MEUNE C, VONK MC et al.: Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUS-TAR) database of systemic sclerosis patients. Ann Rheum Dis. 2010;69:218-21.